Vumerity Alternatives Compared
Vumerity (diroximel fumarate) | Avonex (interferon beta-1a) | Kesimpta (ofatumumab) |
|
---|
Vumerity (diroximel fumarate) | Avonex (interferon beta-1a) | Kesimpta (ofatumumab) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Vumerity (generic name: diroximel fumarate) is an oral prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is given as a twice-daily medicine... View more |
Prescription only
Avonex is a type of interferon beta-1a that may be used to treat adults with multiple sclerosis (MS). It is administered intramuscularly once weekly into the upper thigh. Headache, flu-like... View more |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
||||||||||||||||
More about Vumerity (diroximel fumarate) | More about Avonex (interferon beta-1a) | More about Kesimpta (ofatumumab) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Vumerity has an average rating of 9.4 out of 10 from a total of 6 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Avonex has an average rating of 7.2 out of 10 from a total of 46 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 22% reported a negative effect. |
Kesimpta has an average rating of 6.8 out of 10 from a total of 70 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 19% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Vumerity prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Kesimpta prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
|
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
Other interferon beta-1a brands include: Avonex Pen, Avonex Prefilled Syringe, Rebif, Rebif Rebidose | Other ofatumumab brands include: Arzerra | ||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
1 hour |
3 hours |
1476 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 626 drugs are known to interact with Vumerity:
|
A total of 336 drugs are known to interact with Avonex:
|
A total of 171 drugs are known to interact with Kesimpta:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
October 29, 2019 |
May 17, 1996 |
N/A |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.